Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CLL1 CAR T-Cells in Relapsed or Refractory Acute Myeloid Leukemia
NCT04884984Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2017
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CLL1 CAR-T in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Number of Adverse Events at 12 months. Status: unknown.
02
Drugs
anti-CLL1 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04884984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884984.